The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)
University of Virginia
Summary
This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity. The main questions it will answer includes: * Does exercise combined with weight loss medication reduce body weight and body fat more than weight loss medication alone * Does exercise combined with weight loss medication improve other risk factors more such as the sugar in the blood, cholesterol, fitness, and quality of life Participants will: * Take a weight loss medication (tirzepatide) monthly under the supervision of their primary care physician * (Exercise group only) Will perform exercise \~3 times a week at the University of Virginia). Walking on a treadmill and resistance training * Visit the study site at the beginning of the study and after the study to evaluate weight, body fat, and other health measures
Description
The new type class of weight loss medications called GLP-1 medications have been shown to cause weight loss and improve risk factors for heart disease and diabetes. One thing that is currently unknown is whether exercise augments the impact of weight loss in people taking GLP-1 medication. The EXER-MED study is a pilot study evaluating the effect of 16 weeks of exercise training with GLP-1 medication compared to taking the medication alone. We will evaluate the impact of the study groups on weight, body composition (percent fat, percent lean mass), blood pressure, arterial stiffness, blood wor…
Eligibility
- Age range
- 30–65 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Men and women 30-65 years of age, postmenopausal women included * 27-29.9 with an additional CVD risk factor or 30-40 kg/m2 * For overweight adults only: additional cardiometabolic risk factor (diagnosed dyslipidemia, hypertension) * Willingness and adequate health to go on weight loss medication * The capability and willingness to provide written informed consent * Approval of their primary care provider to go on weight loss medication Exclusion Criteria: * Including but not limited to serious arrhythmias * Cardiomyopathy * Congestive heart failure * Stroke or transie…
Interventions
- DrugTirzepatide
Participants will take tirzepatide under the care of their primary care provider for 16 weeks
- BehavioralExercise
Participants will perform a combination of aerobic and resistance training for 16 weeks
Location
- University of VirginiaCharlottesville, Virginia